Not FDA-approved1Evidence: Limited human dataBrain, nerves and sleep

Semax1

Key takeaway

Semax is a synthetic seven-amino-acid peptide modeled on a fragment of the hormone ACTH. It is a registered drug in Russia, and many of the studies FDA found were published only in Russian.1 It is not an FDA-approved drug, and FDA’s 2026 evaluation found no United States Pharmacopeia or European Pharmacopoeia monograph for it.1 Human data are limited to small, mostly uncontrolled or incompletely reported studies. FDA found insufficient evidence that it works for the uses it evaluated and insufficient information to describe its safety.1 FDA staff recommended against adding Semax to the list of substances pharmacies may use in compounding, but an October 2026 HHS draft policy lists it among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions while FDA’s rulemaking continues.1,5,6

Semax at a glance

What it isA synthetic peptide of seven amino acids, designed from a fragment of adrenocorticotropic hormone (ACTH) without that hormone’s hormonal effects.1
FDA statusNot FDA-approved. FDA staff recommended in May 2026 against adding Semax to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, Semax free base is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,5,6
Human evidenceSmall studies and meeting abstracts, mostly without a control group. The one pain study FDA reviewed in detail found that Semax did not resolve pain for most participants.1
Evidence strengthLimited human data. The only cited human studies are small, short, uncontrolled, or incompletely reported, such as case series, pilot studies, or trials published only as a conference abstract whose methods and results cannot be checked. How this label is assigned

What is Semax?

Semax is a synthetic peptide made of seven amino acids. FDA’s briefing describes it as an analog of a fragment of adrenocorticotropic hormone (ACTH) that lacks the hormone’s effects on the adrenal glands and skin pigment but keeps effects on the nervous system.1

Semax is a registered drug in Russia. There is no monograph for it in the European, Japanese or International Pharmacopoeia.1

FDA could not determine how widely Semax has been used in U.S. compounding. It found Semax widely marketed by wellness and concierge clinics and online retailers for conditions ranging from anxiety and memory to stroke and nerve damage, often without saying whether products were compounded.1

How is Semax thought to work?

How Semax works is poorly understood. In rodents it has been reported to protect nerve cells, reduce clotting, relieve pain, and produce antidepressant-like and anti-anxiety-like effects.1

FDA flags two concerns from these studies. Semax’s possible anti-clotting effect raises a bleeding risk, and in mice it increased the brain’s dopamine response to amphetamine, a pattern FDA associates with drugs of abuse.1

FDA found no studies in people showing how Semax is absorbed or handled by the body.1

What do human studies show?

FDA evaluated Semax for reduced blood flow to the brain (cerebral ischemia), migraine and trigeminal neuralgia, and concluded there is insufficient evidence that it works for any of them.1

The only study FDA reviewed in detail for pain was a small 1996 study without a control group or blinding. A minority of migraine patients reported relief, and the authors themselves concluded that Semax did not show pain-relieving activity on its own in trigeminal neuralgia.1

For cerebral ischemia, FDA found only a meeting abstract that did not report clinical outcomes. Other studies were published in Russian without full English versions, so FDA did not consider them.1

Across the reports FDA found, Semax had been given to between about 100 and 115 adults and to 451 children. Most reports did not discuss side effects, and one reported none.1

FDA’s adverse-event database search through December 2025 found one consumer report, of eye pain and burning with hospitalization in 2024, after using a Semax product.1

What the evidence base contains

  • Small, short, or incompletely reported human study A 1996 study without a control group or blinding in 37 adults with migraine or facial nerve pain. Four of 12 migraine patients reported that their headache stopped, and patients with typical trigeminal neuralgia showed no change in pain.1
  • Small, short, or incompletely reported human study A 2002 meeting abstract on people with chronic reduced blood flow to the brain that did not report the number of patients or clinical outcomes.1
  • Small, short, or incompletely reported human study Other reports FDA found in healthy adults, adults with peptic ulcer, and children with depression or tics. Several are meeting abstracts, most did not discuss side effects, and in some Semax was given alongside other treatments.1
  • Animal or laboratory research Rodent studies reporting nerve-protective, anti-clotting, pain-relieving and antidepressant-like effects through mechanisms FDA describes as poorly understood.1

Evidence-strength label: Limited human data. How this label is assigned

Is Semax FDA-approved?

No. FDA’s May 2026 evaluation states that neither Semax free base nor Semax acetate is a component of an FDA-approved drug and that there is no United States Pharmacopeia monograph for either.1

Under section 503A of the federal drug law, the list of bulk substances that pharmacies can use in compounding, known as the 503A bulks list, is being developed through FDA rulemaking.5

FDA staff evaluated both forms of Semax for that list and recommended against adding either. They cited missing chemical characterization data, insufficient evidence of effectiveness, safety concerns including bleeding risk and possible immune reactions, and existing FDA-approved treatments for most of these conditions.1

FDA’s compounding safety-risk page, last updated April 22, 2026, lists Semax among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.3

HHS’s policy document states that Semax was in FDA’s Category 2, the group of nominated substances that may present significant safety risks, from September 29, 2023 until April 22, 2026, and that neither change altered its status under section 503A.3,6

FDA’s Pharmacy Compounding Advisory Committee discussed Semax on July 24, 2026. HHS’s policy document states that the committee voted in favor of both forms, while FDA’s drug-review center had recommended against listing either form. FDA’s own meeting page, last updated August 6, 2026, lists no vote record.1,2,6

On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians compounding with the peptide substances listed in the policy’s appendix while the 503A list is developed. HHS calls it an interim policy, says it is not binding, and says it may be revisited if safety or quality problems arise.5,6

Appendix A of the policy lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. For Semax, unlike the other five, the policy covers only the free-base form. It applies only when its conditions are met, including a patient-specific prescription, a single listed active ingredient, bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events to FDA.6

HHS and FDA staff weigh the same record differently. HHS’s policy document says newer certificates supply the quality test results FDA staff found missing, that use is now documented, and that the human record FDA staff compiled covers several hundred people with no reported adverse outcome. FDA staff had concluded that the clinical information was insufficient to characterize Semax’s safety.1,6

The policy does not make Semax an FDA-approved drug and is not an FDA rule. HHS notes that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.5,6

Timeline

  1. A small study of Semax in adults with migraine and facial nerve pain is published, the main pain study FDA later reviewed.1
  2. Semax is placed in FDA’s Category 2 of nominated compounding substances that may present significant safety risks, according to HHS’s policy document.6
  3. A Federal Register notice announces the July advisory-committee meeting that will discuss Semax and opens a public comment docket.4
  4. Semax leaves Category 2, according to HHS’s policy document. FDA’s compounding safety-risk page, as last updated that day, lists it among withdrawn nominations.3,6
  5. FDA staff date their evaluation recommending that Semax not be added to the 503A bulks list.1
  6. FDA’s Pharmacy Compounding Advisory Committee discusses Semax.2
  7. HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists Semax among six peptide substances used in compounding.5,6

What is still unknown?

Whether Semax benefits people for any condition: FDA found no adequately reported controlled trial.1

Its safety, including bleeding risk and abuse potential, and how it is absorbed in people.1

What is in products sold under the name: FDA notes that the free-base and acetate forms are distinct substances and that the studies it found did not say which form they used.1

Whether FDA’s rulemaking will add Semax to the 503A list, and how long the October 2026 HHS interim policy will remain in place, remained unresolved in the sources reviewed through November 14, 2026.1,5,6

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Semax: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Semax are the records PeptideScanner has selected and published, not every registration or paper about Semax. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

Not an FDA-approved drug. FDA staff recommended in May 2026 against adding Semax to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists Semax free base among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make Semax an FDA-approved drug.↗↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 15, 2026 · Review version 1.

Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.

Two selected reports examine Semax alongside care for ischemic stroke. They concern specific stroke populations and do not establish effects in healthy people or other indications.↗↗

What the reviewed sources report

The authors reported better functional recovery measures with Semax-containing care. Unclear allocation and masking, concurrent rehabilitation and incomplete harms reporting limit causal conclusions.↗↗

What remains unresolved?

  • Can adequately randomized, masked studies reproduce the reported functional effects?↗↗
  • What do complete reports establish about missing outcomes, concomitant care and safety?↗↗

Read study designs, results, limitations, and sources →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Semax?

Manually reviewed September 15, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

Two selected reports examine Semax alongside care for ischemic stroke. They concern specific stroke populations and do not establish effects in healthy people or other indications.12

Bottom line from this bounded source set

The authors reported better functional recovery measures with Semax-containing care. Unclear allocation and masking, concurrent rehabilitation and incomplete harms reporting limit causal conclusions.12

Reviewed study record

Stroke rehabilitation and functional measures

Design

Patients in early and late rehabilitation groups were subdivided according to whether they received Semax.1

Population

The report included 110 people after ischemic stroke.1

Outcomes reported

The authors reported higher BDNF levels and better Barthel functional scores with Semax-containing care; rehabilitation timing also affected outcomes.1

Limitations

The abstract does not establish random allocation or masking and does not provide a detailed harms account. Concurrent rehabilitation and group differences may confound the findings.1

Reviewed study record

Acute ischemic stroke

Design

A clinical and electrophysiological comparison assessed Semax added to conventional intensive care.2

Population

Thirty Semax-treated patients were compared with eighty conventionally treated patients with reportedly similar stroke severity and lesion location.2

Outcomes reported

The authors described faster neurological recovery, particularly in motor measures.2

Limitations

The abstract does not clearly describe randomization, masking, a prespecified primary endpoint or adverse events. Unequal groups and combined care limit causal interpretation.2

Reviewed source set

  1. PubMed · 29798983[The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. ↗PubMed PMID 29798983 · EFetch XML reviewed 2026-09-15 · payload SHA-256 d3b19c6a367e4f348e077137b88545b77d0f7d13946064454c42ea9cb56701a6
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.17116/jnevro20181183261-68. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 11517472[Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. ↗PubMed PMID 11517472 · EFetch XML reviewed 2026-09-15 · payload SHA-256 2fd5082dacda252f84956f407cddb7c685140b57e9d713c9bce8be1a1409747b
    Crossref check unavailableThe reviewed PubMed payload did not include a DOI, so this source could not be matched to a Crossref work endpoint.
Official-source readings

Official-source update

Reviewed 2026-09-19 · Preserved version 1

The 2026 assessment did not establish the nominated uses

FDA’s briefing found insufficient evidence for cerebral ischemia, migraine and trigeminal neuralgia. The reviewed clinical references had limited methods and outcome information; this is the agency’s scoped assessment. FDA PDF pp. 29 ↗

More findings and the sources behind them

Selected FDA advisory-briefing sections, not a final agency ruling. The source date identifies the committee meeting (July 23–24 for the 2026 packages), not a new approval or final decision.

Uncontrolled symptom reports have limited interpretability

For migraine and trigeminal neuralgia, FDA described small uncontrolled studies with unclear rating scales and incomplete reporting. Before-and-after changes alone cannot distinguish treatment effects from other explanations. FDA PDF pp. 26, 28 ↗

Nonclinical effects are not established clinical benefits

The briefing discusses neurological and other effects in rodents but poorly understood mechanisms and missing toxicology relevant to the proposed subcutaneous route. Those findings cannot be promoted into demonstrated human efficacy. FDA PDF pp. 37 ↗

Form and safety reporting remain important gaps

Clinical references often did not specify free base versus salt, and many did not discuss safety. FDA raised questions about bleeding and injectable-product immunogenicity; these are concerns requiring evidence, not quantified risks established by these reports. FDA PDF pp. 37, 41 ↗

What remains to be checked

  • Check subsequent advisory records and any final FDA action separately from the staff briefing.
  • Retrieve and appraise the original human reports and proposed formulation or route; agency search findings are dated and do not establish a complete worldwide literature review.
Source dates and review coverage

PDF citations use file page numbers. Named webpage sections and registry fields identify the portions read. These are selected readings, not complete source coverage.

  • FDA semax briefing for the July 2026 advisory meeting ↗

    Source dated 2026-07-23; retrieved 2026-09-19.

    • The 2026 assessment did not establish the nominated uses · PDF pp. 29 of 69
    • Uncontrolled symptom reports have limited interpretability · PDF pp. 26, 28 of 69
    • Nonclinical effects are not established clinical benefits · PDF pp. 37 of 69
    • Form and safety reporting remain important gaps · PDF pp. 37, 41 of 69

    SHA-256: 391f5586c1af1cf08d96d1a070c3800786e4e97b6eac069ff94e6fd2c5161599

Open versioned findings and source records →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Primary human administration reports for the specified molecule; other peptides, preclinical experiments and secondary reviews are separate.

207 retrieved · 2 included · 0 excluded · 205 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"semax"[Title/Abstract]

  • Regulator and trial-registry searches and non-indexed reports require separate reconciliation.
  • Full-text appraisal, study-family linkage and citation follow-up remain open.

Showing 25 of 207 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 29798983 — include: Selected human report; abstract and record metadata reviewed. Study families: Semax-stroke-rehabilitation-2018.
  2. PubMed 11517472 — include: Selected human report; abstract and record metadata reviewed. Study families: Semax-stroke-2001.
  3. PubMed 42559144 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  4. PubMed 42195624 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  5. PubMed 42074872 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  6. PubMed 42021992 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  7. PubMed 41490200 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  8. PubMed 42366656 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  9. PubMed 41004910 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  10. PubMed 40692165 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  11. PubMed 41479572 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  12. PubMed 41179234 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  13. PubMed 41171324 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  14. PubMed 40650034 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  15. PubMed 40496623 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  16. PubMed 39604801 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  17. PubMed 39767736 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  18. PubMed 39442746 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  19. PubMed 39418522 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  20. PubMed 37510287 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  21. PubMed 36828803 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  22. PubMed 36553646 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  23. PubMed 35853762 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  24. PubMed 35080861 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.
  25. PubMed 36083821 — not screened: Retrieved record; clinical eligibility has not yet been adjudicated.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"SEMAX"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:27.053033+00:00 · HTTP 404 · SHA-256 57b1e7534d003e4246182162fd2469cdf038de39405056f44fc006715e5496da.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    EMA search

    Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

    0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    Case-insensitive word-boundary identity terms: ["Semax"]

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

    • Document appraisal and national European sources remain open.
    • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

    Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

      EMA search

      Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

      0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

      Search terms, record decisions and remaining work

      Case-insensitive word-boundary identity terms: ["Semax"]

      Source retrievals and payload pins
      • Open the source endpoint ↗

        Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

      • Document appraisal and national European sources remain open.
      • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

      Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

        EMA search

        Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

        0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

        Search terms, record decisions and remaining work

        Case-insensitive word-boundary identity terms: ["Semax"]

        Source retrievals and payload pins
        • Open the source endpoint ↗

          Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

        • Document appraisal and national European sources remain open.
        • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

        Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

          ClinicalTrials.gov search

          ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

          0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

          Search terms, record decisions and remaining work

          "Semax"

          Source retrievals and payload pins
          • Open the source endpoint ↗

            Retrieved 2026-09-15T11:27:04.136508+00:00 · HTTP 200 · SHA-256 b54968c05ff881a1ef7ce604b6a340248f8e2aee8637bef06da0f5693f520df8.

          • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
          • Other registries, unregistered studies and additional aliases remain outside this query.

          Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

            Explore status sources, recent additions, and coverage gaps

            Living status brief

            What is the current status of Semax?

            Not an FDA-approved drug. FDA staff recommended in May 2026 against adding Semax to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists Semax free base among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make Semax an FDA-approved drug.↗↗↗↗

            The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

            Evidence present

            What records are connected here?

            Evidence lanes
            2
            Source years
            11
            Drugs@FDA applications
            0

            These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

            Coverage gaps

            What remains unknown or unsupported?

            PeptideScanner currently has no selected clinical trial records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

            PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

            Explore the Evidence Map and record counts

            Evidence Map v1

            What kinds of records connect to Semax?

            Compare collection coverage →

            This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

            42Selected dated records
            52Connected citations
            11Populated source years2006–2026
            2/4Record lanes present

            Registered human studies

            Trial composition

            0 of 0 selected trial records include at least one phase value; 0 of 0 include a status value in the retained structured contract.

            PubMed bibliography

            Publication composition

            16 of 40 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

            Publication typesJournal Article 15Research Support, Non-U.S. Gov't 10English Abstract 2Letter 1

            Bibliography fields unavailable here for 24 selected records; the records remain visible as metadata observations.

            Regulatory and publication surfaces

            What is structurally connected?

            Drugs@FDA applications
            0
            FDA Federal Register documents
            1
            DailyMed SPL versions
            0
            Canonical profile
            Published
            Profile structured data
            Published
            Linked dated records
            42

            Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

            Profile publication history and record counts
            Source records by collection · 42 dated records

            Research hub

            Explore the Semax evidence record

            Open all 42 records →
            42Dated records
            2Evidence types
            49Cited public sources
            11Source years

            Change ledger

            Recently changed for Semax

            Open all 44 events →

            PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

            Profile status changed

            Semax profile

            We added a plain-language reader guide with cited answers, re-checked FDA’s Semax briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists Semax free base. FDA has not issued a final 503A rule.

            PeptideScanner change date
            November 14, 2026
            Evidence lane
            Profile
            Record added

            Federal Register notice 2026-07361

            The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.

            PeptideScanner change date
            August 21, 2026
            Cited source date
            April 16, 2026
            Evidence lane
            Regulatory

            Official-source collections

            Source records for Semax

            Open the full research atlas →
            PubMed40

            16 with attributed title, venue, publication-date, and type metadata.

            1. Composition of Colon Microbiota in Rats Treated with ACTH(4-7)-PGP Peptide (Semax) under Conditions of Restraint Stress.Bulletin of experimental biology and medicine · 2020 08 01
            2. Influence of ACTG4-7-PGP (Semax) on Morphofunctional State of Hepatocytes in Chronic Emotional and Painful Stress.Bulletin of experimental biology and medicine · 2017 06 03
            3. Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties.Journal of inorganic biochemistry · 2016 08 27
            Explore all selected literature →

            Evidence types

            Coverage by source year

            Selected records span November 15, 2006 to July 24, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

            Continue exploring

            Profiles with overlapping source-year coverage

            Open the research atlas →

            These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

            Organizations and trial records named in cited sources

            Organizations named in cited records

            • U.S. Food and Drug Administration1,2
            • U.S. Department of Health and Human Services5
            Dated updates connected to this profile · 42

            Updates connected to this profile

            Open the full cross-source timeline →
            1. Regulatory

              FDA committee met on seven peptide-related groups of bulk drug substances↗

              FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.↗

            2. Regulatory

              Federal Register notice 2026-07361↗

              The Federal Register published notice 2026-07361, attributed to FDA and its parent HHS department, on 2026-04-16. Its official title is “Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List,” and PeptideScanner's exact reviewed identity mapping connects the document to BPC-157, Emideltide, Epitalon, KPV, MOTS-c, Semax and TB-500.↗

            3. Literature metadata

              Therapeutic possibility of "Semax" for depression.↗

              PubMed lists PMID 18204410 in CNS spectrums as Letter, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-01 (month precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

            4. Literature metadata

              Stability of Semax acetyl to proteolysis in various biological media.↗

              PubMed lists PMID 23652441 in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-05-08 (day precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

            5. Literature metadata

              Study of proteolysis of Semax analogues with different N-terminal amino acids by carboxypeptidases.↗

              PubMed lists PMID 23821053 in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2013-07-03 (day precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

            6. Literature metadata

              Composition of Colon Microbiota in Rats Treated with ACTH(4-7)-PGP Peptide (Semax) under Conditions of Restraint Stress.↗

              PubMed lists PMID 32737723 in Bulletin of experimental biology and medicine as Journal Article, with publication-date metadata of 2020-08-01 (day precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

            7. Literature metadata

              [Proteolysis of semax analogues with different N-terminal amino acids by aminopeptidases].↗

              PubMed lists PMID 22096989 in Bioorganicheskaia khimiia as Journal Article, with publication-date metadata of 2011 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

            8. Literature metadata

              [The binding of Semax, ACTH 4-10 heptapeptide, to plasma membranes of the rat forebrain basal nuclei and its biodegradation].↗

              PubMed lists PMID 15344653 in Bioorganicheskaia khimiia as English Abstract, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2004 May-Jun (source-text precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

            9. Literature metadata

              [Kinetics of Semax penetration into the brain and blood of rats after its intranasal administration].↗

              PubMed lists PMID 16523722 in Bioorganicheskaia khimiia as English Abstract, Journal Article, with publication-date metadata of 2006 Jan-Feb (source-text precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

            10. Literature metadata

              Specific binding of semax in different regions of the rat brain.↗

              PubMed lists PMID 17278839 in Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2006 Sep-Oct (source-text precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

            11. Literature metadata

              Comparative study of analgesic potency of ACTH4-10 fragment and its analog semax.↗

              PubMed lists PMID 18018999 in Bulletin of experimental biology and medicine as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2007-01 (month precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

            12. Literature metadata

              Audiogenic epilepsy in young mice of different strains after neonatal semax treatment.↗

              PubMed lists PMID 19145359 in Bulletin of experimental biology and medicine as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-07 (month precision). PeptideScanner associated the retained record with the identity slug semax. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

            Citations

            Sources

            Coverage and sources →

            Numbered markers in the text point here. Each link opens the original public record.

            1. 1
              FDA briefing document for Semax ↗

              U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

            2. 2
              July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗

              U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

            3. 3
              Certain bulk drug substances for use in compounding that may present significant safety risks ↗

              U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

            4. 4
              Federal Register notice 2026-07361 · published 2026-04-16 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗

              Federal Register via GovInfo · Official source · Source checked August 21, 2026

            5. 5
              Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

              Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

            6. 6
              HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

              U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026